Charles M. Perou

6 ta ish

University of North Carolina at Chapel Hill

1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

   Patricia Cortazar, Lijun Zhang, Michael Untch +34

   Sharh maqola20144 iqtibos

   ABIABI:AkademIndex/2026.other.434433

2. Molecular Subtype of Breast Cancer Metastases Significantly Influences Patient Post-Relapse Survival

   Nicholas P. Tobin, J. Chuck Harrell, Søren Brage +5

   Maqola20143 iqtibos

   ABIABI:AkademIndex/2026.other.434429

3. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

   Thérese Sørlie, Charles M. Perou, Robert Tibshirani +14

   Maqola20013 iqtibos

   ABIABI:AkademIndex/2026.other.434437

4. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

   Roman Rouzier, Charles M. Perou, W. Fraser Symmans +13

   Maqola20053 iqtibos

   ABIABI:AkademIndex/2026.other.434441

5. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

   Kimberly H. Allison, M. Elizabeth H. Hammond, Mitch Dowsett +17

   Maqola20203 iqtibos

   ABIABI:AkademIndex/2026.other.833904

6. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

   Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang +17

   MaqolaOAOchiq kirish20092 iqtibos

   ABIABI:AkademIndex/2026.other.102832